1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229–63.
4. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014;371:1039–49.
6. Carioli G, Malvezzi M, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Ann Oncol 2021;32:478–87.
8. Shin DW, Cho J, Park JH, Cho B. National General Health Screening Program in Korea: history, current status, and future direction. Precis Future Med 2022;6:9–31.
9. Shin SH, Kim SC, Song KB, Hwang DW, Lee JH, Park KM, et al. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: a single-center experience with 2,029 patients. Surgery 2018;164:432–42.
11. Park BK, Seo JH, Han JH, Lee KJ, Son KJ, Choi JK. Trends in treatment patterns and survival outcomes in pancreatic cancer: a nationwide population-based study in Korea. Eur J Cancer 2023;189:112932.
12. Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:157–68.
13. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 2018;268:215–22.
14. Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol 2022;40:1220–30.
15. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernandez-Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018;18:2–11.
18. Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 2001;5:27–35.
20. Verbeke CS. Resection margins and R1 rates in pancreatic cancer: are we there yet? Histopathology 2008;52:787–96.
21. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19:439–57.
23. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020;21:e18–28.
25. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56–61.
26. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1976;37:1519–24.
27. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.
28. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776–84.
29. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–10.
31. Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the National Cancer Data Base. Cancer 2015;121:4141–9.
33. Buss EJ, Kachnic LA, Horowitz DP. Radiotherapy for locally advanced pancreatic ductal adenocarcinoma. Semin Oncol 2021;48:106–10.
34. Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, Korea. Korean clinical practice guideline for pancreatic cancer 2021: a summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. Pancreatology 2021;21:1326–41.
35. Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O’Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34:987–1002.
37. Arcelli A, Guido A, Buwenge M, Simoni N, Mazzarotto R, Macchia G, et al. Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: a multicentric analysis (PAULA-1). Anticancer Res 2020;40:465–72.
39. Mahadevan A, Moningi S, Grimm J, Li XA, Forster KM, Palta M, et al. Maximizing tumor control and limiting complications with stereotactic body radiation therapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 2021;110:206–16.
41. Toesca DA, Ahmed F, Kashyap M, Baclay JR, von Eyben R, Pollom EL, et al. Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiother Oncol 2020;152:63–9.
44. Simoni N, Micera R, Paiella S, Guariglia S, Zivelonghi E, Malleo G, et al. Hypofractionated stereotactic body radiation therapy with simultaneous integrated boost and simultaneous integrated protection in pancreatic ductal adenocarcinoma. Clin Oncol (R Coll Radiol) 2021;33:e31–8.
46. Kim MS. Stereotactic body radiation therapy. J Korean Med Assoc 2008;51:45–52.
49. Dawson LA, Sharpe MB. Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol 2006;7:848–58.
51. Weisz Ejlsmark M, Bahij R, Schytte T, Ronn Hansen C, Bertelsen A, Mahmood F, et al. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer: a phase II study. Radiother Oncol 2024;197:110347.
55. Liermann J, Shinoto M, Syed M, Debus J, Herfarth K, Naumann P. Carbon ion radiotherapy in pancreatic cancer: a review of clinical data. Radiother Oncol 2020;147:145–50.
62. Yang G, Koom WS, Lee BM, Isozaki T, Shinoto M, Yamada S, et al. Reduced risk of severe radiation-induced lymphopenia in carbon ion radiation therapy for locally advanced pancreatic cancer: a comparative analysis of carbon versus photon therapy. Int J Radiat Oncol Biol Phys 2024;May 6 [Epub].
https://doi.org/10.1016/j.ijrobp.2024.04.003.
69. Groot Koerkamp BG, Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, et al. LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial. Ann Oncol 2023;34(Supplement 2):S1323.
70. Sugiura T, Toyama H, Fukutomi A, Asakura H, Takeda Y, Yamamoto K, et al. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04). J Hepatobiliary Pancreat Sci 2023;30:1249–60.
71. Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg 2019;154:1038–48.
72. Hall WA, Evans DB, Tsai S. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX plus radiotherapy in patients with borderline resectable pancreatic cancer: the A021501 trial. JAMA Oncol 2023;9:275–6.
74. Merrell KW, Haddock MG, Quevedo JF, Harmsen WS, Kendrick ML, Miller RC, et al. Predictors of locoregional failure and impact on overall survival in patients with resected exocrine pancreatic cancer. Int J Radiat Oncol Biol Phys 2016;94:561–70.
77. Abrams RA, Winter KA, Goodman KA, Regine W, Safran H, Berger AC, et al. NRG Oncology/RTOG 0848: results after adjuvant chemotherapy+/-chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). J Clin Oncol 2024;42(16 suppl):4005.
78. Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 2016;315:1844–53.
79. Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg 2021;273:341–9.
80. Fietkau R, Ghadimi M, Grutzmann R, Wittel UA, Jacobasch L, Uhl W, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. J Clin Oncol 2022;40(16 suppl):4008.
82. Palm RF, Boyer E, Kim DW, Denbo J, Hodul PJ, Malafa M, et al. Neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreas adenocarcinoma: influence of vascular margin status and type of chemotherapy. HPB (Oxford) 2023;25:1110–20.
83. Parikh PJ, Lee P, Low DA, Kim J, Mittauer KE, Bassetti MF, et al. A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2023;117:799–808.
87. Shi W, Jiang R, Liang F, Yu G, Long J, Zhao J. Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer. Cancer Manag Res 2019;11:5065–73.
88. Sato H, Yoshida R, Yasui K, Umeda Y, Yoshida K, Fuji T, et al. Feasibility of local therapy for recurrent pancreatic cancer. Pancreatology 2022;22:774–81.
93. Comito T, Cozzi L, Zerbi A, Franzese C, Clerici E, Tozzi A, et al. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: a retrospective study. Eur J Surg Oncol 2017;43:735–42.
94. Elamir AM, Karalis JD, Sanford NN, Polanco PM, Folkert MR, Porembka MR, et al. Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes. Int J Radiat Oncol Biol Phys 2022;114:792–802.
96. Stuart CM, Kirsch MJ, Zhuang Y, Meguid CL, Sugawara T, Colborn KL, et al. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Surgery 2023;174:654–9.
98. Giuliante F, Panettieri E, Campisi A, Coppola A, Vellone M, De Rose AM, et al. Treatment of oligo-metastatic pancreatic ductal adenocarcinoma to the liver: is there a role for surgery?: a narrative review. Int J Surg 2024;May 29 [Epub].
https://doi.org/10.1097/JS9.0000000000001665.
100. Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker CL, et al. Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): results of a multicenter, randomized phase II trial. J Clin Oncol 2024;42(3 suppl):603.
103. van Goor IW, Daamen LA, Besselink MG, Bruynzeel AM, Busch OR, Cirkel GA, et al. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE). Trials 2022;23:913.
104. Chang CN, Hsu WT, Li G. Effectiveness and acute toxicity of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in pancreatic cancer: a systematic review and a meta-analysis. Ther Radiol Oncol 2018;2:30.